Biopharmaceuticals/Oncology - Clinical-stage drug development, precision medicine
Strategic Profile
The company's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML), and is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors. The platform focuses on modulating historically difficult-to-target cancer pathways.
Cyborg Score Rationale
Kronos Bio faces significant operational challenges as a recently acquired private company. The organization has been substantially downsized to 8 employees and is dependent on parent company Concentra Biosciences for future capital and development support. Clinical-stage status with no revenue presents inherent uncertainty.
Top Insights
Acquired by Concentra Biosciences in May 2025, transitioning from public to private subsidiary status
Significantly downsized operations with only 8 employees post-acquisition
Lead program (entospletinib) targeting NPM1-mutated AML represents validated cancer target with potential commercial opportunity
Platform expertise in transcription factor modulation addresses historically challenging oncology targets, validated by prior Genentech collaboration
Named Competitors
CDK9 Inhibitors — Competitors developing similar CDK9-targeting cancer therapeutics